搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
BioPharma Dive
8 小时
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
BioPharma Dive
11 小时
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
BioPharma Dive
11 小时
TRex Bio raises $84M to compete in crowded immune drug field
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...
BioPharma Dive
1 天
Metsera raises $215M to accelerate obesity drug plans
After Novo Nordisk and Eli Lilly transformed the market for obesity treatment, a flood of drugmakers has jumped in with ...
BioPharma Dive
1 天
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
BioPharma Dive
1 天
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...
BioPharma Dive
1 天
Viz.ai Wins Prestigious Prix Galien USA Award for Best Digital Health Solution
"We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “For many with HCM, the path to diagnosis and ...
BioPharma Dive
2 天
Neurogene hits a setback in the clinic, days after fundraise
Shares in gene therapy developer Neurogene fell by more than 40% Tuesday after the company disclosed it had learned a ...
BioPharma Dive
2 天
AstraZeneca, Daiichi revise approval plans for Enhertu successor
AstraZeneca and Daiichi Sankyo have changed up their approval plans for a closely watched lung cancer medicine, a decision ...
BioPharma Dive
2 天
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
BioPharma Dive
2 天
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
BioPharma Dive
2 天
FDA lifts pause on Novavax flu vaccine trials
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈